CureVac’s Final Chapter: Delisting Looms as BioNTech Consolidates Ownership

The curtain is set to fall on CureVac's tenure as a publicly traded entity. With BioNTech's public exchange offer now concluded, the timeline for the biotech firm's full integration is clear. For investors still holding shares, the focus has shifted entirely from operational updates to the technical process of an inevitable stock market exit.

This acquisition, valued at approximately $1.25 billion, marks one of the most significant exits in the 2025 biotech landscape. The merger unites two of Germany's foremost mRNA pioneers under a single corporate umbrella. BioNTech has indicated its primary interest lies in leveraging CureVac's technology platforms for oncology research and mRNA production capabilities.

The decisive moment arrived with the expiration of the final acceptance period on December 18, 2025. BioNTech has successfully secured about 86.75 percent of CureVac's outstanding share capital, according to its own statements. This commanding majority effectively ends any possibility of an independent future for the Tübingen-based company.

Should investors sell immediately? Or is it worth buying CureVac?

Market dynamics have already adjusted to reflect the new reality. Trading volume has contracted significantly as institutional investors and arbitrage traders largely closed their positions following the offer period. Share price movements, which have declined roughly 24 percent on a monthly view, are no longer driven by business performance but solely by the formal procedural steps of the acquisition.

The Path Forward for Remaining Shareholders

For the minority shareholders who remain, the legal process is explicitly defined. BioNTech has formally declared its intention to acquire the remaining shares through a squeeze-out procedure. The schedule for this mandatory transfer is tightly sequenced:

• Timeline: The squeeze-out is scheduled for execution in January 2026.
• Legal Mechanism: Remaining shares will be transferred to BioNTech by operation of law or regulatory order.
• Final Step: Subsequently, CureVac's stock will be permanently delisted from all trading venues, including NASDAQ.

The CureVac investment narrative has now reached its conclusion. With the squeeze-out slated for January 2026, the last freely traded shares will be compulsorily transferred and settled. For investors, the story is over, leaving only the wait for the formal financial settlement to be administered by BioNTech.